Background:
In locally advanced gastric cancer (LAGC), perioperative chemotherapy has shown to improve the survival to a larger extent compared to surgery alone. In India, the treatment followed for gastric carcinoma widely varies based on the type of health-care provider and treatment access. There is a paucity of data on the role of neoadjuvant chemotherapy on survival among LAGC patients in the Indian context.
Aim:
The aim of this study was to compare the disease-free survival (DFS) and overall survival (OS) between neoadjuvant and adjuvant chemotherapies among LAGC patients.
Subjects and Methods:
This was a retrospective cohort study involving clinical record review of LAGC patients enrolled between 2015 and 2017 from four tertiary cancer centers in South India. The date for the following events, namely diagnosis, recurrence, death, and last day of visit, was extracted in a mobile-based open-access tool. The median duration of OS and DFS between the neoadjuvant and adjuvant groups was compared using Kaplan–Meier survival curves.
Results:
Of the 137 patients, 70 (51%) had received neoadjuvant chemotherapy followed by surgery and 67 (49%) had adjuvant chemotherapy following the surgery. The mean (standard deviation) age of participants was 55.4 (11.4) years. Seventy-eight percent of the patients were diagnosed at Stage 3 or 4. Regional lymph nodes were involved in 83.9%. The median duration of follow-up was 15 months. The OS in the neoadjuvant and adjuvant groups was 18.6 months and 8.3 months, respectively. Nonregional lymph node involvement and adjacent organ involvement had independently increased the risk of death.
Conclusion:
Among LAGC patients, the neoadjuvant chemotherapy indicated a better median and DFS compared to the adjuvant group. However, these findings were statistically not significant. The current study has contributed an important finding to the existing evidences of clinical practice in an Indian setting. Further large-scale studies are required to validate the promising trend of using neoadjuvant chemotherapy in LAGC.
BACKGROUNDDue to declining global fertility transition and mortality rates, population ageing is a public health challenge. Dementia contributes to a significant proportion of DALY. People with dementia require high level of long-term care and causes burden to the caregivers, both physically and mentally and more prone to depression. The other leading cause of morbidity and mortality in the world is cancer. Because of advancement in palliative care treatment, long-term care is needed for the patients producing definite disturbances in the physical and psychological well-being of the caregivers.The aim of the study is to compare the prevalence of depressive symptoms among the caregivers of patients with Dementia and Cancer.
Background: Injury of the Anterior Cruciate Ligament (ACL) is one of the most frequently encountered knee and ligamentous injuries. MR imaging is an excellent modality for detecting ACL tears. There are several primary and secondary signs of ACL tear. Subjects and Methods: We retrospectively collected data of cases with ACL tear in the Department of Radio-Diagnosis in Rajrajeswari Medical College, Bangalore and studied the primary and secondary signs of ACL tear. Results: A total of 50 cases were analyzed. The most common primary sign was focal abnormal T2 high signal intensity of the ACL. The most common secondary sign was anterior tibial translation of tibia >7mm.
Conclusion:It was concluded that the diagnosis of ACL tear can be made on the basis of primary signs alone, but the secondary signs corroborates the diagnosis. The anterior tibial translation and positive PCL line have higher sensitivity than other secondary signs.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.